Literature DB >> 11931344

Venlafaxine and mirtazapine: different mechanisms of antidepressant action, common opioid-mediated antinociceptive effects--a possible opioid involvement in severe depression?

Shaul Schreiber1, Avi Bleich, Chaim G Pick.   

Abstract

The efficacy of each antidepressant available has been found equal to that of amitriptyline in double-blind studies as far as mild to moderate depression is involved. However, it seems that some antidepressants are more effective than others in the treatment of severe types of depression (i.e., delusional depression and refractory depression). Following studies regarding the antinociceptive mechanisms of various antidepressants, we speculate that the involvement of the opioid system in the antidepressants' mechanism of action may be necessary, in order to prove effective in the treatment of severe depression. Among the antidepressants of the newer generations, that involvement occurs only with venlafaxine (a presynaptic drug which blocks the synaptosomal uptake of noradrenaline and serotonin and, to a lesser degree, of dopamine) and with mirtazapine (a postsynaptic drug which enhances noradrenergic and 5-HT1A-mediated serotonergic neurotransmission via antagonism of central alpha-auto- and hetero-adrenoreceptors). When mice were tested with a hotplate analgesia meter, both venlafaxine and mirtazapine induced a dose-dependent, naloxone-reversible antinociceptive effect following ip administration. Summing up the various interactions of venlafaxine and mirtazapine with opioid, noradrenergic and serotonergic agonists and antagonists, we found that the antinociceptive effect of venlafaxine is influenced by opioid receptor subtypes (mu-, kappa1- kappa3- and delta-opioid receptor subtypes) combined with the alpha2-adrenergic receptor, whereas the antinociceptive effect of mirtazapine mainly involves mu- and kappa3-opioid mechanisms. This opioid profile of the two drugs may be one of the explanations to their efficacy in severe depression, unlike the SSRIs and other antidepressants which lack opioid activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11931344     DOI: 10.1385/JMN:18:1-2:143

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  27 in total

1.  Resolution of treatment-refractory depression with naltrexone augmentation of paroxetine--a case report.

Authors:  R Amiaz; O Stein; P N Dannon; L Grunhaus; S Schreiber
Journal:  Psychopharmacology (Berl)       Date:  1999-04       Impact factor: 4.530

2.  Beneficial effects of nalmefene augmentation in neuroleptic-stabilized schizophrenic patients.

Authors:  M H Rapaport; O Wolkowitz; J R Kelsoe; C Pato; P E Konicki; D Pickar
Journal:  Neuropsychopharmacology       Date:  1993-09       Impact factor: 7.853

3.  The antinociceptive effect of fluvoxamine.

Authors:  S Schreiber; M M Backer; J Yanai; C G Pick
Journal:  Eur Neuropsychopharmacol       Date:  1996-11       Impact factor: 4.600

Review 4.  The treatment of psychotic depression.

Authors:  W Coryell
Journal:  J Clin Psychiatry       Date:  1998       Impact factor: 4.384

5.  Do psychotic, minor and intermittent depressive disorders exist on a continuum?

Authors:  W Coryell
Journal:  J Affect Disord       Date:  1997-08       Impact factor: 4.839

6.  Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative.

Authors:  E A Muth; J T Haskins; J A Moyer; G E Husbands; S T Nielsen; E B Sigg
Journal:  Biochem Pharmacol       Date:  1986-12-15       Impact factor: 5.858

Review 7.  Venlafaxine: a heterocyclic antidepressant.

Authors:  V L Ellingrod; P J Perry
Journal:  Am J Hosp Pharm       Date:  1994-12-15

8.  Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays.

Authors:  A E Takemori; B Y Ho; J S Naeseth; P S Portoghese
Journal:  J Pharmacol Exp Ther       Date:  1988-07       Impact factor: 4.030

Review 9.  Psychotic depression: advances in conceptualization and treatment.

Authors:  S L Dubovsky; M Thomas
Journal:  Hosp Community Psychiatry       Date:  1992-12

Review 10.  The pharmacologic profile of mirtazapine.

Authors:  T de Boer
Journal:  J Clin Psychiatry       Date:  1996       Impact factor: 4.384

View more
  18 in total

1.  Beta-endorphins as possible markers for therapeutic drug monitoring.

Authors:  Radivoj Jadrić; Emina Kiseljaković; Sabaheta Hasić; Mira Winterhalter-Jadrić
Journal:  Bosn J Basic Med Sci       Date:  2007-02       Impact factor: 3.363

2.  Paroxetine for somatic pain associated with physical illness: a review.

Authors:  Prakash S Masand; Meera Narasimhan; Ashwin A Patkar
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

3.  Interaction of different antidepressants with acute and chronic methadone in mice, and possible clinical implications.

Authors:  Shaul Schreiber; Yonatan Barak; Avner Hostovsky; Renana Baratz-Goldstein; Ina Volis; Vardit Rubovitch; Chaim G Pick
Journal:  J Mol Neurosci       Date:  2013-09-22       Impact factor: 3.444

4.  Evidence for the involvement of opioid system in the antidepressant-like effect of ascorbic acid.

Authors:  Morgana Moretti; Camille M Ribeiro; Vivian B Neis; Luis Eduardo B Bettio; Priscila B Rosa; Ana Lúcia S Rodrigues
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-12-08       Impact factor: 3.000

5.  Differential effects of oxycodone and venlafaxine on resting state functional connectivity-A randomized placebo-controlled magnetic resonance imaging study.

Authors:  Tine M Hansen; Dina Lelic; Anne E Olesen; Asbjørn Mohr Drewes; Jens B Frøkjaer
Journal:  CNS Neurosci Ther       Date:  2018-02-21       Impact factor: 5.243

6.  Repeated administration of mirtazapine attenuates oxaliplatin-induced mechanical allodynia and spinal NR2B up-regulation in rats.

Authors:  Xiaoyu Liu; Guangfen Zhang; Lin Dong; Xingming Wang; Heliang Sun; Jinchun Shen; Weiyan Li; Jianguo Xu
Journal:  Neurochem Res       Date:  2013-07-09       Impact factor: 3.996

7.  κ-Opioid receptors are not necessary for the antidepressant treatment of neuropathic pain.

Authors:  Salim Megat; Yohann Bohren; Stephane Doridot; Claire Gaveriaux-Ruff; Brigitte L Kieffer; Marie-José Freund-Mercier; Ipek Yalcin; Michel Barrot
Journal:  Br J Pharmacol       Date:  2014-12-01       Impact factor: 8.739

8.  Does trazodone have a role in palliating symptoms?

Authors:  Mellar P Davis
Journal:  Support Care Cancer       Date:  2006-11-28       Impact factor: 3.603

9.  Mu-opioid receptors are not necessary for nortriptyline treatment of neuropathic allodynia.

Authors:  Yohann Bohren; Dzenan Karavelic; Luc-Henri Tessier; Ipek Yalcin; Claire Gavériaux-Ruff; Brigitte L Kieffer; Marie-José Freund-Mercier; Michel Barrot
Journal:  Eur J Pain       Date:  2009-12-28       Impact factor: 3.931

Review 10.  Antidepressants for the treatment of chronic pain.

Authors:  Bénédicte Verdu; Isabelle Decosterd; Thierry Buclin; Friedrich Stiefel; Alexandre Berney
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.